Drug Search Results

MKC-253

Alternative Names: mkc-253, mkc253, mkc 253
Latest Update: 2023-03-17
Latest Update Note: PubMed Publication

Product Description

For Diabetes Mellitus, Type 2 (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00475371)

Mechanisms of Action: GLP-1 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mannkind
Company Location: WESTLAKE VILLAGE CA 91362
Company CEO: Michael E. Castagna
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MKC-253

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Trial	Phase	Trial Status	Disease	Primary Completion Date
MKC-253-002	P1	Completed	Type 2 Diabetes	2008-09-01
2007-003430-42	P2	Completed	Type 2 Diabetes	2008-06-10
MKC-253-001	P1	Completed	Type 2 Diabetes	2007-06-01

Recent News Events

Date	Type	Title
03/17/2023	PubMed	Glucoregulatory disruption in male mice offspring induced by maternal transfer of endocrine disrupting brominated flame retardants in DE-71.
12/18/2022	PubMed	Substance P and Glucagon-like Peptide-1(7-36) Amide Mediate Anorexic Responses to Trichothecene Deoxynivalenol and Its Congeners.
04/05/2022	PubMed	Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions